Response to Comment on Tang et al. Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial. Diabetes Care 2015;38:1339–1346

Tang, An; Rabasa‐Lhoret, Rémi; Castel, Hélène; Wartelle-Bladou, Claire; Gilbert, Guillaume; Massicotte-Tisluck, Karine; Chartrand, Gabriel; Olivié, Damien; Julien, Anne–Sophie; Guise, Jacques de; Soulez, Gilles; Chiasson, Jean‐Louis

doi:10.2337/dc15-1091

Cited by 3 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, Cuthberson et al [64] reported a significant 42% reduction in liver triglyceride content in 25 patients with T2DM treated either with exenatide or liraglutide for 6 months, that correlated with an improvement in glycemic control but not with weight loss. Other small uncontrolled studies have reported variable benefit with GLP-1RA [65][66][67], although reduction in hepatic steatosis has not been observed in all studies [68].…”

Section: Metforminmentioning

confidence: 87%

Pharmacological management of nonalcoholic fatty liver disease

Barb¹,

Portillo-Sánchez²,

Cusi³

2016

Metabolism

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) affects one-third of the population and two-thirds of patients with obesity or type 2 diabetes (T2DM). Its more aggressive form is known as nonalcoholic steatohepatitis (NASH) and is characterized by hepatocyte necrosis, inflammation and often fibrosis. The presence of fibrosis indicates a more aggressive course and may lead to cirrhosis. Premature mortality in NASH is related to both hepatic (cirrhosis and hepatocellular carcinoma) and extra-hepatic complications, largely cardiovascular disease (CVD). Many therapeutic agents have been tested, but still none approved specifically for NASH. Treatment of NAFLD includes aggressive management of diabetes and cardiovascular risk factors, although the role of controlling hyperglycemia per se in patients with T2DM and NASH remains unknown. Agents tested with some success in non-diabetic patients with NASH include pioglitazone, liraglutide, vitamin E and to a lesser degree, pentoxiphylline. In patients with T2DM and NASH only pioglitazone has shown to significantly improve liver histology, with only a handful of patients with diabetes having been studied with other modalities. This review focuses on available agents for NASH to assist clinicians in the management of these complex patients. Many novel compounds are being studied and will likely make combination therapy for NASH a reality in the future.

show abstract

Section: Metforminmentioning

confidence: 87%

Pharmacological management of nonalcoholic fatty liver disease

Barb¹,

Portillo-Sánchez²,

Cusi³

2016

Metabolism

View full text Add to dashboard Cite

show abstract

“…У крыс лираглутидная терапия улучшала инсулинорезистентность и стеатоз печени путем активации АМФактивированной протеинкиназы [46]. Совместное применение лираглутида и инсулина гларгин у пациентов с СД 2-го типа не имело преимущества перед отдельным их применением при гликемии и стеатозе печени [47]. Добавление лираглутида или ситаглиптина к метформину у пациентов с СД 2-го типа в течение 26 недель приводило к снижению веса и уменьшению стеатоза печени и висцеральной жировой ткани.…”

Section: ошибка 7 предположение что возраст пациента его повышенный вес будут снижать выживаемость при трансплантации печени или бариатриunclassified

Non-Alcoholic Fatty Liver Disease: How to Avoid Mistakes in Patient’s Curation

Ливзан¹,

Кролевец²,

Костоглод³

et al. 2021

EPh

View full text Add to dashboard Cite

The high prevalence of non-alcoholic fatty liver disease and its association with diseases of the metabolic profile causes the interest of doctors of various specialties in the management of patients with this pathology. Due to the accumulation of data on risk factors and disease progression, approaches and attitudes about previously harmless pathology have evolved to understand its potential danger. The formation of the correct approach to the management of patients with non-alcoholic fatty liver disease is a priority task. In this publication, we have analyzed and systematized data from literature concerning the most common problems (mistakes) in the curation of patients with non-alcoholic fatty liver disease.

show abstract

“…Dou et al applied a strongly supervised method to segment the volume of three-dimensional liver CT. This is achieved by using deconvolution layers to the middle and features and applying SoftMax layers to encrypt the classification output [1]. Their results not only demonstrate good convergence but also reduce training and validation errors.…”

Section: Introductionmentioning

confidence: 99%

Applied Study of Medical Image Segmentation Based on Convolutional Neural Network

Ding,

Huang

2024

HSET

View full text Add to dashboard Cite

Medical image segmentation is one of the hot topics in today's research, and researchers have found that medical image segmentation has important application prospects and potentials in the diagnosis and treatment of diseases, however, there are still some challenges and problems in the practical application. Therefore, the research topic of this paper is the research of medical image segmentation applications based on convolutional neural networks. The research methodology of this paper is to analyze the application of existing deep learning algorithms in image segmentation. It is found that the medical image segmentation method based on the convolutional neural network can effectively improve the accuracy and efficiency of segmentation results. The reliability of segmentation can be further improved by introducing medical experts' knowledge and labeled data. In summary, the research in this paper shows that the medical image segmentation method based on convolutional neural networks has the potential and advantages to improve the accuracy and efficiency of segmentation.

show abstract

Response to Comment on Tang et al. Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial. Diabetes Care 2015;38:1339–1346

Cited by 3 publications

References 5 publications

Pharmacological management of nonalcoholic fatty liver disease

Pharmacological management of nonalcoholic fatty liver disease

Non-Alcoholic Fatty Liver Disease: How to Avoid Mistakes in Patient’s Curation

Applied Study of Medical Image Segmentation Based on Convolutional Neural Network

Contact Info

Product

Resources

About